O'Melveny Reps Chinese Co. In $118M Complete Genomics Deal

Law360, New York (September 17, 2012, 5:28 PM EDT) -- Gene sequencing company Complete Genomics Inc. has agreed to let a U.S. subsidiary of Chinese rival BGI-Shenzhen snap it up in a merger deal worth about $117.6 million, the companies announced Monday.

Complete shareholders will receive $3.15 per share in the deal, a 54 percent premium over the $2.04 Complete stock closed at on June 4, the last day of trading before a previous temporary trading halt following a significant share price slide. The troubled Mountain View, Calif.-based company had said the halt would let it...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.